Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 1251, pseudogene (RNU6-1251P) is a processed pseudogene of the U6 small nuclear RNA (snRNA) family[3][4]. The canonical U6 snRNA is an essential component of the spliceosome, a complex involved in pre-mRNA splicing, and participates directly in the catalysis of intron removal in the cell nucleus[1]. In contrast, RNU6-1251P is a pseudogene, meaning it is a non-functional genomic copy of the U6 snRNA. Such pseudogenes typically arise through L1 (LINE-1)-mediated retrotransposition events, resulting in sequence copies that lack the regulatory or structural features necessary for expression or biological function[4]. RNU6-1251P does not encode a functional small nuclear RNA and does not participate in splicing or other cell processes. There is no evidence this pseudogene is used as a direct therapeutic target, is involved in any disease mechanism, or interacts with drugs[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1251, pseudogene (RNU6-1251P).